Terms: = Sarcomas AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
49 results:
1. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
[TBL] [Abstract] [Full Text] [Related]
2. Novel KMT2B gene mutation in MUC4 positive low-grade fibromyxoid sarcoma.
Zhang L; Luo L; Liu C; Li Z
Diagn Pathol; 2024 Feb; 19(1):30. PubMed ID: 38347522
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
4. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
5. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract] [Full Text] [Related]
6. FDA Approval Summary: Selpercatinib for the treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
7. Resistance and endurance exercise training improves muscle mass and the inflammatory/fibrotic transcriptome in a rhabdomyosarcoma model.
Collao N; Sanders O; Caminiti T; Messeiller L; De Lisio M
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):781-793. PubMed ID: 36797054
[TBL] [Abstract] [Full Text] [Related]
8. Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J; Peña KB; Riu F; Lucia-Gozálvez C; Vidaller A; Maldonado V; Parada D
Pathobiology; 2023; 90(4):281-288. PubMed ID: 36731433
[TBL] [Abstract] [Full Text] [Related]
9. Exceptional response to neoadjuvant targeted therapy with the selective ret inhibitor selpercatinib in ret-fusion-associated sarcoma.
Schrenk KG; Weschenfelder W; Spiegel C; Agaimy A; Stöhr R; Hartmann A; Gaßler N; Drescher R; Freesmeyer M; Malouhi A; Bürckenmeyer F; Aschenbach R; Teichgräber U; Kögler C; Vogt M; Hofmann GO; Hochhaus A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5493-5496. PubMed ID: 36469155
[TBL] [Abstract] [Full Text] [Related]
10. TFG::MET-rearranged soft tissue tumor: A rare infantile neoplasm with a distinct low-grade triphasic morphology.
Michal M; Ud Din N; Švajdler M; Klubíčková N; Ptáková N; Hájková V; Michal M; Agaimy A
Genes Chromosomes Cancer; 2023 May; 62(5):290-296. PubMed ID: 36464850
[TBL] [Abstract] [Full Text] [Related]
11. Receptor Tyrosine Kinase Inhibitors for the treatment of Recurrent and Unresectable Bone sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract] [Full Text] [Related]
12. An integrative pan cancer analysis of ret aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
13. Mesenchymal neoplasms with NTRK and other kinase gene alterations.
Davis JL; Al-Ibraheemi A; Rudzinski ER; Surrey LF
Histopathology; 2022 Jan; 80(1):4-18. PubMed ID: 34958503
[TBL] [Abstract] [Full Text] [Related]
14. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract] [Full Text] [Related]
15. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
[TBL] [Abstract] [Full Text] [Related]
16. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract] [Full Text] [Related]
17. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract] [Full Text] [Related]
18. A low-grade malignant soft tissue tumor with S100 and CD34 co-expression showing novel CDC42SE2-BRAF fusion with distinct features.
Sheng SJ; Li JM; Zou YF; Peng XJ; Wang QY; Fang HS; Li X; Ding Y; Fan QH; Zhang ZH; Wei YZ; Gong QX
Genes Chromosomes Cancer; 2020 Oct; 59(10):595-600. PubMed ID: 32447786
[TBL] [Abstract] [Full Text] [Related]
19. [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].
Shao Y; Zhong D
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):381-387. PubMed ID: 32429639
[TBL] [Abstract] [Full Text] [Related]
20. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
[TBL] [Abstract] [Full Text] [Related]
[Next]
